Brief: BrainStorm Cell Therapeutics To Unveil Phase 3b NurOwn Trial Design
27/02/2024 12:47
Feb 27 (Reuters) - Brainstorm Cell Therapeutics Inc
BCLI.O :
* BRAINSTORM CELL THERAPEUTICS TO UNVEIL PHASE 3B NUROWN®
TRIAL
DESIGN AT MDA CLINICAL AND SCIENTIFIC CONFERENCE
Source text for Eikon: ID:nPn2x1B0da
Further company coverage: BCLI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Brainstorm Cell Therapeutics
See all newsBrief: Brainstorm Appoints Former FDA Associate Commissioner Peter J. Pitts As Executive Chairman
Brief: Brainstorm Cell Therapeutics Announces First Quarter 2026 Financial Results And Provides Corporate Update
Brief: Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing At Premium To Market
Brief: Brainstorm Cell Therapeutics Announces Second Quarter Financial Results
Brainstorm Cell Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview